CHMP5 and COVID-19: Recently, we have developed a potent SARS-CoV-2 neutralizing human mAb HB27, which targets the receptor binding domain (RBD) of spike (S) protein,15 and the therapeutic efficacy against mild or moderated COVID-19 patients are being evaluated in phase II clinical trials (NCT04644185).